K-BROVET - potassium bromide solution
Pegasus Laboratories, Inc.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

--------

Description:
K-BroVet Oral Solution is a butterscotch vanilla flavored solution containing 250 mg/mL of potassium bromide, cyanocobalamin and pyridoxine HCl.

How Supplied:
Oral Solution, 10 FL OZ (300 mL), NDC 49427-245-07
Oral Solution, 2 FL OZ (59 mL), NDC 49427-245-03

Storage Conditions:
Store in a tightly sealed container at room temperature (59-86°F).

Indication:
K-BroVet potassium bromide is used to treat seizure disorders in dogs. It can be used in addition to therapy with other agents or as the sole anticonvulsant.

Contraindications:
K-BroVet should not be used in animals with a history of hypersensitivity to Bromide or any of the components of the solution or tablets.

Dosage and Administration:
Recommended Dosage for K-BroVet Oral Solution:

To achieve a serum level of approximately 1 mg/mL, give 120 mg/kg PO daily for 5 days then reduce to 30 mg/kg PO once daily. To achieve a serum level of approximately 1.5 mg/mL, give 160 mg/kg PO for 5 days and then reduce to 40 mg/kg PO once daily thereafter. (R-21)

Among dogs responses to bromide may vary, treatment should be tailored to the individual dog, based on serum bromide concentration, success of seizure control, and the observation of adverse effects. Steady state serum concentrations generally take 4 to 5 months in dogs; therapeutic concentrations may be reached before steady state at about 4 weeks after the beginning of treatment, serum bromide concentration may be tested to assess the response to product and, if results are satisfactory, the next testing for steady state serum levels is typically about 4 months. If the dog’s serum concentration is within range and the dog is doing well in the therapeutic range, serum concentration may then be tested every 6 to 12 months. Serum bromide is typically evaluated at the end of the loading period, then as described above when an animal is started with a loading dose.
Dogs -- An oral dose of 30 mg of Bromide per kg of body weight every twelve hours for 115 days produced a steady state serum concentration of 2.45 mg/mL (range, 1.78 to 2.69 mg/mL) in Beagles fed a diet containing 0.55% chloride. (R-3)

**Warnings:**
This medication should be used cautiously in older animals as they will be more susceptible to adverse effects. This medication is not indicated for use in cats.

**Caution:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.
For Veterinary Use Only
Not for Human Use
KEEP OUT OF REACH OF CHILDREN AND ANIMALS

**Possible Side Effects:**
Dog may experience drowsiness when taking K-BroVet, but this will generally go away after approximately 3 weeks. Increased hunger, thirst, urination, vomiting, constipation, anorexia, and uncoordinated movements may occur with K-BroVet. During the load in dose increased nausea may be experienced.
There is no information on the relative frequency of pancreatitis in dogs associated with bromide therapy alone. However, pancreatitis has been reported to be more frequent in dogs on concurrent phenobarbital and bromide therapy than dogs on phenobarbital alone. (R-12)
Personality changes have been occasionally reported in dogs on bromide, including attention seeking, irritability or aggression, and aimless pacing.

**Reproduction/Pregnancy/Lactation:**
The effects of bromide on canine reproduction have not been studied.

**Young Dogs:**
Safety of administering bromide to neonates and young animals has not been evaluated. (R-16-17)

**Drug Interactions and/or Related Effects:**
Drug interactions and/or related effects have been selected on the basis of their clinical significance (possible mechanism in parentheses where appropriate) - not necessarily inclusive (* = major clinical significance):

Note: Any of the following medications taken in combinations, depending on the amount taken, could also interact with K-BroVet.

Medications and foods containing bromide and chloride compete for reabsorption by the kidneys; increased amounts of chloride can promote loss of bromide in the urine, leading to a lowering of serum bromide concentrations: Decreased chloride consumption will promote increased renal reabsorption of bromide. (R-1;2;4;5-7,15)
Halothane anesthesia (when inhaled a percentage of halothane is metabolized by dogs to produce bromide, along with other compounds); peak serum concentration occurs within about a day and, in one group of dogs, ranged from 0.04 to 0.088 mg/mL and persisted, with some diminishment, for at least ten days. (R-10; 11) Consideration should be given to animals that must have repeated anesthesia or that already require high serum bromide concentration for seizure control. Increased bromide levels due to metabolism of halothane are unlikely to be a significant risk for bromide toxicity in most dogs.

**Pharmacology:**

**Mechanism of Action/Effect:**

Bromide's mechanism of action has not been clearly defined. By preferential movement across neuronal membranes via gamma-amino butyric (GABA) - activated chloride channels, bromide may aid in controlling seizures through hyperpolarization of neuronal cell membranes, leading to stabilization and decreased sensitivity to epileptic foci. (R-2; 15)

**Volume of Distribution:**

Dogs: $0.45 \pm 0.07 \text{ L/kg}$ (R-4)

Protein binding: Bromide is minimally protein bound. (R-20)

Biotransformation: Bromide is not biotransformed by the liver and is eliminated unchanged, primarily by renal clearance. (R-2)

**Half-life Elimination:**

Bromide is freely filtered by the glomerulus, but is reabsorbed by the kidneys, in competition with chloride. (R-7)

Bromide reabsorption will predominate in the absence of a large chloride load, causing a significantly extended elimination half-life in dogs. (R-4; 5; 7)

Increasing chloride intake by an animal on a low chloride diet will decrease the half life of elimination. (R-14; 15)

**Elimination:**

Renal. Because bromide is widely distributed, minute amounts will also be excreted in saliva, sweat and feces. (R-5; 6) Rate of elimination of bromide will increase in dogs that receive a high level of chloride supplementation. (R-4)

**Overdose:**

For more information in cases of overdose or unintentional ingestion, contact the American Society for the Prevention of Cruelty to Animals (ASPCA) National Animal Poison Control Center (888-426-4435 or 900-443-000; a fee may be required for consultation) and/or the drug manufacturer.

Note: Signs of bromide toxicity are dose-related but dogs differ in their sensitivity. Bromide toxicity has rarely been reported in dogs with serum bromide concentrations of less than 1.5 mg/mL. Signs have been reported in some dogs with relatively low serum concentration (2.75 mg/mL) while not appearing in other dogs with significantly higher concentration (4 mg/mL). (R-3; 18) Dogs on concurrent bromide and phenobarbital therapy may be prone to bromide toxicity at lower serum concentrations than when bromide is administered alone. Other physical factors may also play a role in sensitivity. (R-3)

Short-term bromide toxicity is considered completely reversible. (R-18) However, mild bromide toxicity can progress to more severe nervous system dysfunction with ongoing high serum concentration of bromide. (R-8)

Other species - Bromide toxicity has also been reported in cattle, goats, and horses fed hay that
contained bromide ion residue from accidental treatment with methyl bromide. Signs included ataxia, hind limb weakness, joint swelling, and sedation or recumbency. (R-9)

**Clinical effects of overdose:**

Clinical signs may appear with serum bromide concentration > 1.5 mg/mL in dogs on bromide therapy alone, but become more common as serum concentration increases, and most common when serum concentration exceeds 4 mg/mL in dogs receiving bromide as the only anticonvulsant (2 to 3 mg/mL in dogs receiving concurrent phenobarbital and bromide). (R-3;18)

*Ataxia; diarrhea; hematochezia; salvation, excessive; shivering; skin lesions; stupor, progressing to coma and death - Reported with a dose of 200 to 500 mg/kg a day for 4 to 26 weeks.* (R-13)

**Treatment of bromide toxicity.** Recommended treatment consist of the following:

- For dogs on concurrent phenobarbital and bromide therapy with mild sedation, ataxia or hind leg weakness, a 10 to 25% reduction in phenobarbital may resolve the signs within five to seven days. (R-19)
- For dogs receiving bromide as the only anticonvulsant, K-BroVet may be discontinued for a few days while monitoring serum concentration, to see if mild signs of toxicity will resolve.
- If necessary, renal excretion of bromide may be accelerated by increasing sodium chloride consumption or administering 0.9% sodium chloride intravenously over twelve hours, depending on the severity of the toxicity. (R-7;8;13)
- Supportive treatment
- Continue to monitor

**References:**

6. USP Committee comment. Rec 9/9/04.
12. Gaskill CL, Cribb AE. Pancreatitis associated with potassium bromide/phenobarbital combination


20. USP Committee comment, Rec 11/01/04.


10 FL OZ (300 mL) Bottle Label
2 FL OZ (59 mL) Bottle Label

Contains:
Potassium Bromide . . . 250 mg/mL
Also contains cyanocobalamin,
pyridoxine HCl and butterscotch
vanilla flavor.
CAUTION: Federal law restricts this
drug to use by or on the order of a
licensed veterinarian.
For Veterinary Use Only
Not for Human Use
KEEP OUT OF REACH OF CHILDREN
AND ANIMALS
Store at room temperature (59-86°F).

Recommended Dosage:
For a loading dose to achieve a serum
level of approximately 1 mg/mL, give
120 mg/kg PO daily for 5 days and
then reduce to 30 mg/kg PO once
daily. To achieve a serum level of
approximately 1.5 mg/mL, give 160
mg/kg PO for 5 days and then reduce
to 40 mg/kg PO once daily thereafter.

Rev. 9-2014

For additional product informa-
tion, see fold-out booklet.

MANUFACTURED FOR
PRN PHARMACAL
Employee-Owned
PENSACOLA, FL 32514

2 FL OZ (59 mL) Box Label
**K-BROVET**

potassium bromide solution

## Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRESCRIPTION ANIMAL DRUG</td>
<td>NDC:49427-245</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>ORAL</td>
</tr>
</tbody>
</table>

## Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>POTASSIUM BROMIDE (UNII: OSD78555ZM) (BROMIDE ION - UNII:952902IX06)</td>
<td>POTASSIUM BROMIDE</td>
<td>250 mg in 1 mL</td>
</tr>
</tbody>
</table>

## Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYANOcobalamin (UNII: P6YC3EG204)</td>
<td>0.01 mg in 1 mL</td>
</tr>
<tr>
<td>PYRIDOXINE HYDROCHLORIDE (UNII: 68Y4CF58BV)</td>
<td>0.79 mg in 1 mL</td>
</tr>
</tbody>
</table>
### Product Characteristics

<table>
<thead>
<tr>
<th>Color</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>pink</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Shape</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Flavor</th>
<th>Imprint Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUTTERSCOTCH, VANILLA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contains</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:49427-245-07</td>
<td>300 mL in 1 BOTTLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:49427-245-03</td>
<td>1 in 1 BOX</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>59 mL in 1 BOTTLE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>unapproved drug other</td>
<td></td>
<td>02/23/2009</td>
<td></td>
</tr>
</tbody>
</table>

### Labeler

**Labeler** - Pegasus Laboratories, Inc. (108454760)

### Registrant

**Registrant** - Pegasus Laboratories, Inc. (108454760)

### Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pegasus Laboratories, Inc.</td>
<td></td>
<td>108454760</td>
<td>analysis, manufacture, label</td>
</tr>
</tbody>
</table>

Revised: 12/2017